Cambrex was approached by a top 100 European-based pharmaceutical company looking for a development and manufacturing partner to assist with an in-licensed product originating from an emerging pharma company. The molecule was in clinical Phase II / III trials and the customer required development work and scale-up to commercial manufacturing. The chemistry required was particularly challenging and Cambrex needed to upgrade its commercial manufacturing assets prior to project initiation.
Cambrex Karlskoga, Sweden, was selected to assist with the project as the company had an existing relationship with the originator company and extensive experience with the chemistry and process. The customer also felt that Cambrex had the necessary scale-up and commercial production expertise.